Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Depreciation & Amortization (CF) (2019 - 2025)

Benitec Biopharma's Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $13000.0 for Q1 2025.

  • For Q1 2025, Depreciation & Amortization (CF) fell 48.0% year-over-year to $13000.0; the TTM value through Mar 2025 reached $78000.0, down 4.88%, while the annual FY2024 figure was $87000.0, 36.03% down from the prior year.
  • Depreciation & Amortization (CF) for Q1 2025 was $13000.0 at Benitec Biopharma, down from $14000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $67000.0 in Q1 2021 and bottomed at $6000.0 in Q2 2022.
  • The 5-year median for Depreciation & Amortization (CF) is $26000.0 (2024), against an average of $33000.0.
  • The largest annual shift saw Depreciation & Amortization (CF) plummeted 88.46% in 2022 before it surged 250.0% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $55000.0 in 2021, then dropped by 25.45% to $41000.0 in 2022, then plummeted by 58.54% to $17000.0 in 2023, then fell by 17.65% to $14000.0 in 2024, then fell by 7.14% to $13000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Depreciation & Amortization (CF) are $13000.0 (Q1 2025), $14000.0 (Q4 2024), and $25000.0 (Q3 2024).